Takeda to invest ¥100B for new plasma-derived drugs facility in Japan

Takeda Pharmaceutical (NYSE:TAK) said on Thursday that it will invest about ¥100B to build a new manufacturing facility for plasma-derived therapies (PDTs) in Osaka, Japan.

The Japanese drugmaker noted that it was the company's largest ever investment in manufacturing capacity expansion in Japan.

The new site will be the largest of its kind in Japan and is anticipated to be operational by around 2030.

This is not the only investment Takeda is making, keeping an eye on PDTs demand. In September 2022, the company said it would invest ~€300M for a production facility in Belgium for manufacturing PDTs for people with rare and complex chronic diseases.

Takeda added that the facility will increase the capacity of its current plasma manufacturing site in Narita, Japan by almost five-fold.

The facility will be a fully integrated plant, consisting of teardown, fractionation, purification, filling, finishing capabilities and cold storage warehouse, according to the company.

The facility will provide a plasma fractionation capacity of more than 2M liters per year, noted Thomas Wozniewski, global manufacturing & supply officer at Takeda.

"Takeda has delivered plasma therapies to meet the needs of patients in Japan for more than 70 years. This new investment will strengthen our ability to continuously and reliably bring high-quality PDTs to a growing number of patients in Japan and worldwide," said Milano Furuta, president, Japan Pharma Business Unit, Takeda.

Takeda expects no financial impact on its operating results for the fiscal year ending March 31, 2023 (FY2022) due to this investment.